Morningstar® Stock Report™

Novo Nordisk A/S NOVO B

Letzte Unternehmensnews

DatumZeitQuelleTitelTyp
Previous Stories...
08.03.202418:42NASDAQNEWSWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
05.03.202409:53NASDAQNEWSNovo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
04.03.202414:29NASDAQNEWSNovo Nordisk A/S - share repurchase programme
26.02.202411:02NASDAQNEWSNovo Nordisk A/S - share repurchase programme
21.02.202414:03NASDAQNEWSNotice for the Annual General Meeting of Novo Nordisk A/S
19.02.202414:29NASDAQNEWSNovo Nordisk A/S – Share repurchase programme
14.02.202411:59NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12.02.202416:22NASDAQNEWSNovo Nordisk A/S - share repurchase programme
12.02.202412:13NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08.02.202414:55NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06.02.202418:43NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06.02.202407:20NASDAQNEWSNovo Nordisk A/S - share repurchase programme
05.02.202411:04NASDAQNEWSNovo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
01.02.202419:51NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
31.01.202406:30NASDAQNEWSNovo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
30.01.202415:28NASDAQNEWSNovo Nordisk A/S - share repurchase programme
22.01.202412:01NASDAQNEWSNovo Nordisk A/S - share repurchase programme
15.01.202410:43NASDAQNEWSNovo Nordisk A/S - share repurchase programme
09.01.202416:15NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08.01.202412:49NASDAQNEWSCOMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes